Summary
BeiGene, Ltd. (ONC) reported its first-quarter 2022 financial results, showcasing a significant surge in product revenue, which more than doubled compared to the prior year period, primarily driven by strong sales of BRUKINSA® and tislelizumab in key markets like the U.S. and China. This growth was further bolstered by the inclusion of new products like BLINCYTO®, KYPROLIS®, and POBEVCY® in its distribution portfolio. However, total revenue experienced a substantial decline year-over-year, largely due to the absence of a significant upfront collaboration payment from Novartis that was recognized in the prior year quarter. Despite the revenue shift, the company's product sales demonstrate robust underlying demand, supported by expanding reimbursement coverage. Operationally, BeiGene reported a net loss for the quarter, a reversal from the net income in the prior year, primarily due to a substantial increase in research and development (R&D) and selling, general, and administrative (SG&A) expenses. These increased expenses reflect the company's strategic investments in expanding its global development organization, clinical pipeline, commercial capabilities, and broader R&D activities. The company maintained a strong liquidity position with significant cash and short-term investments, providing a runway for its ongoing operations and development programs.
Financial Highlights
54 data points| Revenue | $306.63M |
| Cost of Revenue | $65.24M |
| Gross Profit | $241.39M |
| R&D Expenses | $389.92M |
| SG&A Expenses | $294.57M |
| Operating Expenses | $749.91M |
| Operating Income | -$443.29M |
| Interest Expense | $5.53M |
| Net Income | -$435.20M |
| EPS (Basic) | $-0.33 |
| EPS (Diluted) | $-0.33 |
| Shares Outstanding (Basic) | 1.33B |
| Shares Outstanding (Diluted) | 1.33B |
Key Highlights
- 1Product revenue surged by 146.5% to $261.6 million, driven by strong sales of BRUKINSA® and tislelizumab, and the addition of new in-licensed products.
- 2Total revenue decreased by 49.4% to $306.6 million, primarily due to the absence of a significant upfront collaboration payment from Novartis recognized in the prior year quarter.
- 3Net loss for the quarter was $434.3 million, compared to a net income of $66.5 million in the prior year, reflecting increased R&D and SG&A expenses.
- 4Research and Development (R&D) expenses increased by 21.6% to $389.9 million, driven by the expansion of global development organization and clinical programs.
- 5Selling, General, and Administrative (SG&A) expenses increased by 61.8% to $294.6 million, reflecting investments in commercial expansion and growing business operations.
- 6Cash, cash equivalents, and restricted cash stood at $4.4 billion, and short-term investments were $1.9 billion, indicating a strong liquidity position.
- 7The company ended the quarter with an accumulated deficit of $5.4 billion.